BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Anakinra readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Anakinra\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06336733-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:Anakinra: Phase 3 readout est. (NCT06336733)
DESCRIPTION:Anakinra\, phase 3.\nStudy: Randomized Controlled Trial in Pati
 ents on Long-term Colchicine With Colchicine-resistant Familial Mediterran
 ean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment f
 or Painful Attacks in Patients Who Refuse Continuous Daily Therapy\nEstima
 ted primary completion: 4 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/anakinra#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06336733
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03968913-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Anakinra: Phase 1 readout est. (NCT03968913)
DESCRIPTION:Anakinra\, phase 1.\nStudy: Biologic Therapy to Prevent Osteoar
 thritis After ACL Injury\nEstimated primary completion: 30 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03968913
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05177822-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Anakinra: Phase 2 readout est. (NCT05177822)
DESCRIPTION:Anakinra\, phase 2.\nStudy: Interleukin-1 Blockade in Acute Myo
 cardial Infarction to Prevent Heart Failure\nEstimated primary completion:
  22 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/an
 akinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05177822
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04656184-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Anakinra: Phase 3 readout est. (NCT04656184)
DESCRIPTION:Anakinra\, phase 3.\nStudy: A Trial Comparing the Efficacy and 
 Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment\, 
 in Patients With Kawasaki Disease Who Failed to Respond to Initial Standar
 d IVIG Treatment\nEstimated primary completion: March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04656184
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04926467-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Anakinra: Phase 2 readout est. (NCT04926467)
DESCRIPTION:Anakinra\, phase 2.\nStudy: Chemotherapy + Anakinra in Patients
  With Pancreatic Adenocarcinoma (PDAC)\nEstimated primary completion: June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04926467
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410312-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Anakinra: Phase 1 readout est. (NCT07410312)
DESCRIPTION:Anakinra\, phase 1.\nStudy: BRIDGE - Blocking Receptor of IL-1
 β for Donor Graft Edema Reduction\nEstimated primary completion: August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410312
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04148430-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Anakinra: Phase 2 readout est. (NCT04148430)
DESCRIPTION:Anakinra\, phase 2.\nStudy: A Study of Anakinra to Prevent or T
 reat Severe Side Effects for Patients Receiving CAR-T Cell Therapy\nEstima
 ted primary completion: October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/anakinra#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04148430
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05805930-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Anakinra: Phase 3 readout est. (NCT05805930)
DESCRIPTION:Anakinra\, phase 3.\nStudy: Therapeutic Approach in Colchicine-
 resistant Recurrent pEricarditis in Children\nEstimated primary completion
 : 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ana
 kinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05805930
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888348-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Anakinra: Phase 1/2 readout est. (NCT07888348)
DESCRIPTION:Anakinra\, phase 1/2.\nStudy: Anakinra for Prevention of Poor G
 raft Function in MDS Allo-HSCT\nEstimated primary completion: 15 November 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07888348
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03587701-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anakinra: Phase 2 readout est. (NCT03587701)
DESCRIPTION:Anakinra\, phase 2.\nStudy: Effects of Anakinra in Subjects Wit
 h Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inn
 er Ear Disease\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03587701
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Anakinra: Phase 2 readout est. (NCT07138898)
DESCRIPTION:Anakinra\, phase 2.\nStudy: Immunosuppressant Management in Rhe
 umatology Patients Undergoing Elective Total Shoulder Arthroplasty\nEstima
 ted primary completion: January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/anakinra#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05926505-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Anakinra: Phase 2/3 readout est. (NCT05926505)
DESCRIPTION:Anakinra\, phase 2/3.\nStudy: Safety and Efficacy of Anakinra T
 reatment for Patients With Post Acute Covid Syndrome\nEstimated primary co
 mpletion: March 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /anakinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05926505
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267821-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Anakinra: Phase 2/3 readout est. (NCT05267821)
DESCRIPTION:Anakinra\, phase 2/3.\nStudy: Targeted Reversal of Inflammation
  in Pediatric Sepsis-induced MODS\nEstimated primary completion: 15 May 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05267821
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Anakinra: Phase 3 readout est. (NCT02735707)
DESCRIPTION:Anakinra\, phase 3.\nStudy: Randomized\, Embedded\, Multifactor
 ial Adaptive Platform Trial for Community- Acquired Pneumonia\nEstimated p
 rimary completion: June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/anakinra#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT02735707
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06381661-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280809
DTEND;VALUE=DATE:20280810
SUMMARY:Anakinra: Phase 2 readout est. (NCT06381661)
DESCRIPTION:Anakinra\, phase 2.\nStudy: Adaptive Platform Trial for Personn
 alisation of Sepsis Treatment in Children and Adults: a Multi-national\, T
 reatable Traits-guided\, Adaptive\, Exploratory\, Bayesian Basket Trial\nE
 stimated primary completion: 9 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/anakinra#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06381661
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Anakinra: Phase 3 readout est. (NCT04381936)
DESCRIPTION:Anakinra\, phase 3.\nStudy: Randomised Evaluation of COVID-19 T
 herapy\nEstimated primary completion: 30 September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/anakinra#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04381936
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600190-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Anakinra: Phase 1 readout est. (NCT07600190)
DESCRIPTION:Anakinra\, phase 1.\nStudy: Anakinra Rescue Treatment for Moder
 ate Asthma Attacks (ARTMA)\nEstimated primary completion: 1 January 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07600190
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503834-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20290407
DTEND;VALUE=DATE:20290408
SUMMARY:Anakinra: Phase 1/2 readout est. (NCT07503834)
DESCRIPTION:Anakinra\, phase 1/2.\nStudy: "IL-1β Blockade to Prevent Immun
 othrombosis in Recipients of a Pancreatic Organ"\nEstimated primary comple
 tion: 7 April 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 nakinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07503834
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838974-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Anakinra: Phase 1 readout est. (NCT07838974)
DESCRIPTION:Anakinra\, phase 1.\nStudy: Adding Anakinra and Tocilizumab to 
 Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years o
 f Age or Older\nEstimated primary completion: 1 November 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07838974
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371689-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Anakinra: Phase 3 readout est. (NCT07371689)
DESCRIPTION:Anakinra\, phase 3.\nStudy: ANAKINRA IN THE TREATMENT OF PEDIAT
 RIC ACUTE MYOCARDITIS\nEstimated primary completion: December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07371689
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281027-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Anakinra: Phase 3 readout est. (NCT07281027)
DESCRIPTION:Anakinra\, phase 3.\nStudy: COMparison Between Anakinra and Toc
 ilizumab in NORSE - "COMBAT-NORSE"\nEstimated primary completion: 31 March
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/anakinra#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07281027
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974877-3446@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Anakinra: Phase 1 readout est. (NCT06974877)
DESCRIPTION:Anakinra\, phase 1.\nStudy: Repeat PET/CT Imaging in People Wit
 h CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide 
 to Measure Changes in Organ-Specific Amyloid Load\nEstimated primary compl
 etion: 1 July 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 nakinra#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06974877
URL:https://assetmemo.bio/drug/anakinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
